Table 1 Patient characteristics
ID | Initial Gleason score | ISUP/ D’Amico | Ablation mode | Initial PSA ng/ml | Follow-up PSA ng/ml | Follow-up MRI-PI-RADS | Follow-up histopathology from MRI/ultrasound fusion-guided biopsy, infield (i) / outfield (o) | Specific characteristic |
|---|---|---|---|---|---|---|---|---|
1 | 7a | 2/ir | focal | 8 | 4.22 | 4 | 7a (i + o) | artifact during TULSA |
2 | 7a | 2/ir | focal | 7.1 | 4.1 | 4 | 7a (o) | |
3 | 7a | 2/ir | focal | 5 | 2.9 | 2 | no malignancy | |
4 | 7a | 2/ir | focal | 10.3 | 1.59 | 2 | no malignancy | |
5 | 6 | 1/lr | whole-gland | 6.2 | 0.01 | 2 | NA | |
6 | 7a | 2/ir | whole-gland | 7.05 | 0.15 | 2 | no malignancy | |
7 | 7a | 2/ir | focal | 9.15 | 0.75 | 2 | no malignancy | |
8 | 7a | 2/ir | focal | 8.1 | 4.6 | 2 | no malignancy | |
9 | 6 | 1/lr | whole-gland | 9.5 | 0.34 | 2 | no malignancy | |
10 | 7a | 2/ir | focal | 5.5 | 5.5 | 2 | NA | |
11 | 7a | 2/ir | focal | 3.46 | 4.23 | 4 | 7a (i + o) | |
12 | 7a | 2/ir | focal | 7.3 | 0.43 | 2 | no malignancy | |
13 | 6 | 1/lr | focal | 6.4 | 3.25 | 2 | NA | |
14 | 7a | 2/ir | whole-gland | 8.8 | 0.71 | 2 | NA | |
15 | 7a | 2/ir | focal | 9.1 | 2.37 | 2 | no malignancy | |
16 | 7a | 2/ir | focal | 5.5 | 1.4 | 2 | NA | |
17 | 7a | 2/ir | focal | 7.13 | 1.26 | 2 | no malignancy | |
18 | 6 | 1/lr | focal | 5 | NA | NA | Lost to follow-up | |
19 | 7a | 2/ir | focal | 2.6 | 1.78 | 3 | 7b (o) | |
20 | 7a | 2/ir | focal | 5.33 | 3.05 | 4 | NA | Lymph-node metastasis diagnosed with PSMA-PET |
Salvage treatment after previous radiotherapy | ||||||||
21 | No GS after radiotherapy | whole-gland, salvage | 4.5 | 0.08 | 3 | no malignancy | Later diagnosed with bone metastasis | |
22 | No GS after radiotherapy | whole-gland, salvage | 9.53 | 0.06 | NA | NA | Patient refused MRI and Biopsy at PSA 0.1 ng/ml | |